Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|June 9, 2022
Daily Medication Pearl: Citalopram (Celexa)
Author(s)Saro Arakelians, PharmD
Citalopram (Celexa) is indicated for the treatment of major depressive disorder in adults.
Advertisement
Medication Pearl of the Day: Citalopram (Celexa)
Indication: Citalopram (Celexa) is a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in adults.
Insight:
- Dosing: Initial dosage is 20 mg once daily. After 1 week may increase to maximum dosage of 40 mg once daily.
- Dosage forms: Tablets 10 mg, 20 mg scored; and 40 mg, scored.
- Adverse events: The most common adverse reaction (incidence ≥ 5% and twice placebo) is ejaculation disorder (primarily ejaculation delay).
- Mechanism of action: The mechanism of action of citalopram is unclear but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin.
Source:
Advertisement
Related to this article
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
5